References:
[1] Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration, BMJ. 308 (1994) 81–106.
[2] Antithrombotic Trialists’ Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ. 324 (2002) 71–86. https://doi.org/10.1136/ bmj.324.7329.71. [3] N.W. Russo, G. Petrucci, B. Rocca, Aspirin, stroke and drug-drug interactions, Vascul Pharmacol. 87 (2016) 14–22. https://doi.org/10.1016/ j.vph.2016.10.006. [4] E.H. Awtry, J. Loscalzo, Aspirin, Circulation. 101 (2000) 1206–1218. https://doi.org/10.1161/01.cir.101.10.1206. [5] M.L. Kowalski, J.S. Makowska, M. Blanca, S. Bavbek, G. Bochenek, J. Bousquet, P. Bousquet, G. Celik, P. Demoly, E.R. Gomes, E. NiżankowskaMogilnicka, A. Romano, M. Sanchez-Borges, M. Sanz, M.J. Torres, A. De Weck, A. Szczeklik, K. Brockow, Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*, Allergy. 66 (2011) 818– 829. https://doi.org/10.1111/ j.1398-9995.2011.02557.x. [6] M.L. Kowalski, R. Asero, S. Bavbek, M. Blanca, N. Blanca-Lopez, G. Bochenek, K. Brockow, P. Campo, G. Celik, J. Cernadas, G. Cortellini, E. Gomes, E. Niżankowska-Mogilnicka, A. Romano, A. Szczeklik, S. Testi, M.J. Torres, S. Wöhrl, J. Makowska, Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs, Allergy. 68 (2013) 1219–1232. [7] R.A. Settipane, H.P. Constattine, G.A. Settipane, Aspirin Intolerance and Recurrent urticaria in Normal Adults and Children, Allergy. 35 (1980) 149–154.https://doi.org/10.1111/j.1398-9995.1980.tb01730.x. [8] J.E. Kim, J.W. Lee, J.M. Sung, J.H. Kim, G.S. Choi, Y.M. Ye, D.H. Nahm, H.S. Park, Comparison of Clinical Characteristics between Acute and Chronic Acetylsalicylic Acid-Intolerant Urticaria, Korean Journal of Asthma, Allergy and Clinical Immunology. 30 (2010) 93–99.
[9] S.-H. Kim, J.-H. Choi, K.-W. Lee, S.-H. Kim, E.-S. Shin, H.-B. Oh, C.-H. Suh, D.-H. Nahm, H.-S. Park, The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria, Clinical & Experimental Allergy. 35 (2005) 339–344. https://doi.org/10.1111/j.1365-2222.2004.02197.x.
[10] Significant association of FcɛRIα promoter polymorphisms with aspirin-intolerant chronic urticaria - ScienceDirect, (n.d.). https://www.sciencedirect.com/science/article/abs/pii/S0091674906021208 (accessed March 29, 2023). [11] S.-H. Kim, Y.-M. Kang, S.-H. Kim, B.-Y. Cho, Y.-M. Ye, G.-Y. Hur, H.-S. Park, Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria, Allergy. 64 (2009) 213–221.https://doi.org/10.1111/j.1398-9995.2008.01795.x.[12] Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin‐induced urticaria | British Journal of Dermatology | Oxford Academic, (n.d.). https://academic.oup.com/bjd/article/163/5/977/6644091 (accessed March 29, 2023). [13]. Doña I, Blanca-López N, Torres MJ, García-Campos J, García-Núñez I, Gómez F, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22(5):363–71. [14] E.R. Gomes, P. Demoly, Epidemiology of hypersensitivity drug reactions, Curr Opin Allergy Clin Immunol. 5 (2005) 309–316. https://doi.org/10.1097/01.all.0000173785.81024.33.
[15] K. Brockow, M.R. Ardern-Jones, M. Mockenhaupt, W. Aberer, A. Barbaud, J.-C. Caubet, R. Spiewak, M.J. Torres, C.G. Mortz, EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity, Allergy. 74 (2019) 14–27. https://doi.org/10.1111/all.13562.
[16] A.B. Shrestha, S. Shrestha, P.K. Yadav, L. Adhikari, A. Yadav, Cefixime induced Steven Johnson syndrome: A case report from Bangladesh, Ann Med Surg (Lond). 79 (2022) 104089.https://doi.org/10.1016/j.amsu.2022.104089.
[17] B.S. Hebron, H.J. Hebron, Aspirin sensitivity: acetylsalicylate or excipients, Internal Medicine Journal. 39 (2009) 546–549. https://doi.org/10.1111/j.1445-5994.2009.01973.x.
[18] W.Y.W. Yeung, H.S. Park, Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity, Yonsei Med J. 61 (2020) 4–14. https://doi.org/10.3349/ymj.2020.61.1.4.
[19] P. Schaefer, Acute and Chronic Urticaria: Evaluation and Treatment, Am Fam Physician. 95 (2017) 717–724.
[20] T. Zuberbier, A.H. Abdul Latiff, M. Abuzakouk, S. Aquilina, R. Asero, D. Baker, B. Ballmer-Weber, C. Bangert, M. Ben-Shoshan, J.A. Bernstein, C. Bindslev-Jensen, K. Brockow, Z. Brzoza, H.J. Chong Neto, M.K. Church, P.R. Criado, I.V. Danilycheva, C. Dressler, L.F. Ensina, L. Fonacier, M. Gaskins, K. Gáspár, A. Gelincik, A. Giménez-Arnau, K. Godse, M. Gonçalo, C. Grattan, M. Grosber, E. Hamelmann, J. Hébert, M. Hide, A. Kaplan, A. Kapp, A. Kessel, E. Kocatürk, K. Kulthanan, D. Larenas-Linnemann, A. Lauerma, T.A. Leslie, M. Magerl, M. Makris, R.Y. Meshkova, M. Metz, D. Micallef, C.G. Mortz, A. Nast, H. Oude-Elberink, R. Pawankar, P.D. Pigatto, H. Ratti Sisa, M.I. Rojo Gutiérrez, S.S. Saini, P. Schmid-Grendelmeier, B.E. Sekerel, F. Siebenhaar, H. Siiskonen, A. Soria, P. Staubach-Renz, L. Stingeni, G. Sussman, A. Szegedi, S.F. Thomsen, Z. Vadasz, C. Vestergaard, B. Wedi, Z. Zhao, M. Maurer, The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria, Allergy. 77 (2022) 734–766.https://doi.org/10.1111/all.15090.
[21] M.L. Kowalski, R. Asero, S. Bavbek, M. Blanca, N. Blanca-Lopez, G. Bochenek, K. Brockow, P. Campo, G. Celik, J. Cernadas, G. Cortellini, E. Gomes, E. Niżankowska-Mogilnicka, A. Romano, A. Szczeklik, S. Testi, M.J. Torres, S. Wöhrl, J. Makowska, Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs, Allergy. 68 (2013) 1219–1232.https://doi.org/10.1111/all.12260.
[22] C.A. Naranjo, U. Busto, E.M. Sellers, P. Sandor, I. Ruiz, E.A. Roberts, E. Janecek, C. Domecq, D.J. Greenblatt, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther. 30 (1981) 239–245. https://doi.org/10.1038/clpt.1981.154.